AI-generated summary
This study protocol describes a planned triple blind randomized controlled trial of red-light photobiomodulation added to standard care for radiodermatitis in 96 Brazilian women with breast cancer undergoing radiotherapy. The authors report that the trial will compare skin reactions, thermal images and quality of life against a placebo control, and that it has not yet produced results. The authors state that the expected benefit is not yet demonstrated.
- Participants
- 96
- Who or what was studied
- Women undergoing radiotherapy for breast cancer in Brazil
- Wavelengths
- 660 nm
- Limits stated in the abstract
- This is a study protocol for an ongoing trial, so no outcome results are reported yet.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 10.16 J/cm2
- Power
- 100mW
- Total energy
- 1 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Randomized controlled trial, Trial registration, Control group, Wound healing, Inflammation, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.